ArticleFrontiers in immunology2026
3'-hydroxypuerarin mitigates LPS-induced acute lung injury by inhibiting TLR4 activation-mediated NF-κB p65/NLRP3/GSDMD signaling.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The landscape of protein post-translational modifications in the pathogenesis of acute respiratory distress syndrome.Journal of thoracic disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Acute lung injury (ALI) is a common critical respiratory illness. 3'-Hydroxypuerarin (3HP), a beneficial isoflavone from Methods: To investigate the role of 3HP in mitigating ALI, Results: 3HP significantly reduced IL6 and TNF-α levels in bronchoalveolar lavage fluid (BALF) and serum, attenuated pulmonary edema, inhibited the mRNA levels of chemokines and inflammatory factors in lung tissues, and suppressed the expression of IL1β, IL6, TNF-α, HMGB1, TLR4, MyD88, p-IκBα (S32/S36), p-NF-κB p65 (S536), COX2, iNOS, ICAM1, VCAM1, NLRP3, ASC, Caspase-1, Cleaved Caspase-1 (Ala317) p10, NEK7, Caspase-8, IL18, GSDMD, and GSDMD N-terminal both in lung tissues and in RAW264.7 cells, indicating that 3HP inhibited LPS-stimulated TLR4 activation, thereby reducing IκBα phosphorylation and degradation, and preventing NF-κB p65 nuclear translocation to mediate the transcription and expression of inflammatory mediators. It also inhibited NLRP3 inflammasome activation, decreased Caspase-1 cleavage of GSDMD, and lowered the release of the pore-forming GSDMD N-terminal structural domain, blocking the immune response to pyroptosis. Moreover, the NLRP3 inhibitor MCC950 enhanced the effect of 3HP on acute cellular inflammatory injury. Notably, molecular docking and dynamics simulation revealed that 3HP stably bound to TLR4. Resatorvid (TAK-242), a selective TLR4 signaling inhibitor, significantly enhanced 3HP's inhibitory effect on TLR4, further indicating that 3HP may block the NF-κB p65/NLRP3/GSDMD signaling pathway by inhibiting TLR4 activation in response to LPS stimulation. Conclusions: Our results demonstrated that 3HP mitigates LPS-induced ALI by inhibiting TLR4 activation-mediated NF-κB p65/NLRP3/GSDMD signaling. These findings provide scientific evidence for the clinical treatment of ALI and present new insights into the pharmacological role of 3HP in mitigating acute lung inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.